Compare · ALBT vs ARGX
ALBT vs ARGX
Side-by-side comparison of Avalon GloboCare Corp. (ALBT) and argenx SE (ARGX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ALBT and ARGX operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $63.27B, about 15444.7x ALBT ($4.1M).
- Over the past year, ALBT is down 87.0% and ARGX is up 44.0% - ARGX leads by 131.0 points.
- ARGX has been more active in the news (11 items in the past 4 weeks vs 9 for ALBT).
- ARGX has more recent analyst coverage (25 ratings vs 0 for ALBT).
- Company
- Avalon GloboCare Corp.
- argenx SE
- Price
- -
- -
- Market cap
- $4.1M
- $63.27B
- 1M return
- -20.29%
- +14.62%
- 1Y return
- -87.00%
- +43.97%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- News (4w)
- 9
- 11
- Recent ratings
- 0
- 25
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Latest ALBT
- Avalon GloboCare Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
- SEC Form S-8 filed by Avalon GloboCare Corp.
- Avalon GloboCare Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
- SEC Form 10-Q filed by Avalon GloboCare Corp.
- SEC Form SCHEDULE 13G filed by Avalon GloboCare Corp.
- SEC Form PRE 14A filed by Avalon GloboCare Corp.
- SEC Form S-1 filed by Avalon GloboCare Corp.
- Director Mathews Michael converted options into 62,280 shares (SEC Form 4)
- Avalon GloboCare Corp. filed SEC Form 8-K: Unregistered Sales of Equity Securities
- Avalon GloboCare Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
Latest ARGX
- argenx downgraded by Deutsche Bank
- Amendment: SEC Form SC TO-T/A filed by argenx SE
- SEC Form 6-K filed by argenx SE
- Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
- argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
- Amendment: SEC Form SC TO-T/A filed by argenx SE
- argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc.
- SEC Form SC TO-T filed by argenx SE
- Guggenheim resumed coverage on argenx with a new price target
- SEC Form 6-K filed by argenx SE